Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Up to know, three is few large-scale, randomized study prospectively and simultaneously
comparing the efficacy, adverse effects and patient compliance of high-dose dual therapy
(HDDT) with or without bismuth versus amoxicillin-metronidazole bismuth quadruple therapy
(AM-BQT) as first-line regimens for H. pylori eradication.
The aims of this study are:
1. to compare the efficacy of HDDT with or without bismuth and AM-BQT as first-line
regimens for H. pylori eradication;
2. to compare the patient adherence and adverse effects of these treatment regimens;
3. to investigate factors that may influence H. pylori eradication by these treatment
regimens;
4. to identify the effect of H. pylori eradication on the evolution of ecosystem of
microbiota, and inflammatory parameters.